Emer­gent TV ads book­end its tu­mul­tuous year. Can mil­i­tary, Nar­can work help re­hab its brand?

When the Covid-19 pan­dem­ic hit, Emer­gent BioSo­lu­tions was rel­a­tive­ly un­known. But the con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CD­MO) sud­den­ly hit the spot­light when it nabbed a mas­sive $628 mil­lion gov­ern­ment deal in mid-2020 to man­u­fac­ture John­son & John­son and As­traZeneca Covid-19 vac­cines.

Emer­gent saw an op­por­tu­ni­ty to in­tro­duce the pub­lic to its brand. Along with its CD­MO work, Emer­gent makes its own vac­cines and com­mer­cial meds, in­clud­ing the Nar­can opi­oid re­ver­sal agent, as well as med­ical coun­ter­mea­sure prod­ucts like small­pox and an­thrax vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER